Compare ADMA Biologics Inc (ADMA) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Bank of Nova Scotia — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Bank of Nova Scotia trades at $89.03 (market cap $107.95B). The key difference: Bank of Nova Scotia is far larger — about 49.5× ADMA Biologics Inc's market cap, and Bank of Nova Scotia pays a 3.65% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BNS | |
|---|---|---|
Market Cap | $2.18B | $107.95B |
Sector | Health | Financials |
52-Week High | $20.38 | $90.29 |
52-Week Low | $7.60 | $56.41 |
Enterprise Value | $2.25B | — |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Bank of Nova Scotia (BNS) trades at $88.85, up 0.6% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong analyst support, a 52.63% buy rating, and a solid dividend yield. Revenue grew to $37.10B in 2025, though net income margin dipped slightly to 20.99%.
Outlook is positive with earnings growth and strategic acquisitions like MapleMark Bank driving upside. Risks include economic sensitivity and competitive pressures. Wall Street sentiment leans bullish, but investors should monitor credit conditions and interest rate impacts on banking performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
